Last reviewed · How we verify
dexketoprofen trometamol + pethidine hydrochloride
Dexketoprofen trometamol and pethidine hydrochloride work together to provide potent analgesia by reducing inflammation and acting on opioid receptors in the central nervous system.
Dexketoprofen trometamol and pethidine hydrochloride is a combination analgesic used for the management of moderate to severe pain. Dexketoprofen trometamol is a nonsteroidal anti-inflammatory drug (NSAID) that reduces inflammation and pain, while pethidine hydrochloride is an opioid analgesic that acts on the central nervous system to relieve pain. The combination provides a synergistic effect, enhancing pain relief and reducing the required dose of each component. However, the use of this combination is limited due to potential side effects and the risk of dependency associated with opioids. It is primarily used in hospital settings for postoperative pain management.
At a glance
| Generic name | dexketoprofen trometamol + pethidine hydrochloride |
|---|---|
| Sponsor | Kavaklıdere Umut Hospital |
| Drug class | ["NSAID", "opioid analgesic"] |
| Target | ["cyclooxygenase (COX) enzymes", "mu-opioid receptors"] |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
Dexketoprofen trometamol inhibits cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins that cause pain and inflammation. Pethidine hydrochloride binds to mu-opioid receptors in the brain and spinal cord, reducing the perception of pain.
Approved indications
Boxed warnings
- Risk of respiratory depression, addiction, abuse, and misuse
Common side effects
- Nausea
- Dizziness
- Somnolence
- Vomiting
- Constipation
Drug interactions
- CNS depressants (e.g., benzodiazepines, alcohol)
- Anticoagulants
- Diuretics
- ACE inhibitors
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
| TR2019000001 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: